

Jan Steffel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3103026/publications.pdf>

Version: 2024-02-01

95
papers

11,625
citations

159525

30
h-index

51562

86
g-index

98
all docs

98
docs citations

98
times ranked

11529
citing authors

#	ARTICLE	IF	CITATIONS
1	Right ventricular only pacing for cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 70-71.	0.7	2
2	Development and validation of a risk score for predicting pericardial effusion in patients undergoing leadless pacemaker implantation: experience with the Micra transcatheter pacemaker. <i>Europace</i> , 2022, 24, 1119-1126.	0.7	25
3	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
4	Predictors of left atrial fibrosis in patients with atrial fibrillation referred for catheter ablation. <i>Cardiology Journal</i> , 2022, 29, 413-422.	0.5	7
5	Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter-defibrillators: A propensity-matched analysis from a multicenter European registry. <i>Heart Rhythm</i> , 2022, 19, 1109-1115.	0.3	15
6	Patient Related Outcomes of Mechanical lead Extraction Techniques (PROMET) study: A comparison of two professions. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, , .	0.5	1
7	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f30-f39.	1.4	33
8	Assessment of injury current during leadless pacemaker implantation. <i>International Journal of Cardiology</i> , 2021, 323, 113-117.	0.8	2
9	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
10	Exercise intolerance “ from spiroergometry to transdiaphragmatic myocardial punch biopsy: a case report of isolated cardiac sarcoidosis. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa121.	0.3	0
11	Leadless pacemaker tools used beyond device implantation. <i>HeartRhythm Case Reports</i> , 2021, 7, 83-86.	0.2	0
12	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
13	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	0.7	18
14	Transvenous lead extraction: The influence of age on patient outcomes in the PROMET study cohort. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1540-1548.	0.5	4
15	Stereotactic radioablation of ventricular arrhythmias in patients with structural heart disease “ A systematic review. <i>Radiotherapy and Oncology</i> , 2021, 162, 132-139.	0.3	22
16	Distinctive characteristics of his bundle potentials in patients with atrioventricular nodal reentrant tachycardia. <i>Cardiology Journal</i> , 2021, , .	0.5	0
17	2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment“Authors“™ reply. <i>Europace</i> , 2021, 23, 1685-1686.	0.7	22
18	Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation: Authors“™ reply. <i>Europace</i> , 2021, 23, 1686-1687.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Long-term follow-up after cardiac resynchronization therapy-optimization in a real-world setting: A single-center cohort study. <i>Cardiology Journal</i> , 2021, 28, 728-737.	0.5	2
20	Persistent left superior vena cava transvenous lead extraction: A European experience. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, , .	0.8	5
21	The year in cardiology: arrhythmias and pacing. <i>European Heart Journal</i> , 2020, 41, 619-625c.	1.0	2
22	Case Report: New-onset Retinal Migraine After Transseptal Catheterization. <i>Headache</i> , 2020, 60, 463-468.	1.8	4
23	Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a long-term retrospective cohort study. <i>ESC Heart Failure</i> , 2020, 7, 2773-2783.	1.4	4
24	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>European Journal of Heart Failure</i> , 2020, 22, 2349-2369.	2.9	101
25	The subcutaneous ICD for prevention of sudden cardiac death: Current evidence and future directions. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1421-1427.	0.5	5
26	Extraction of a leadless pacemaker 23 months after implantation. <i>European Heart Journal</i> , 2020, 41, 2038-2038.	1.0	5
27	First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia. <i>Radiotherapy and Oncology</i> , 2020, 152, 203-207.	0.3	59
28	Results of the Patient-Related Outcomes of Mechanical lead Extraction Techniques (PROMET) study: a multicentre retrospective study on advanced mechanical lead extraction techniques. <i>Europace</i> , 2020, 22, 1103-1110.	0.7	57
29	A square root pattern of changes in heart rate variability during the first year after circumferential pulmonary vein isolation for paroxysmal atrial fibrillation and their relation with long-term arrhythmia recurrence. <i>Kardiologia Polska</i> , 2020, 78, 209-218.	0.3	10
30	The year in cardiology: arrhythmias and pacing – The year in cardiology 2019. <i>Cardiologia Croatica</i> , 2020, 15, 132-145.	0.0	0
31	Stroke Prevention with Non-Vitamin K Oral Anticoagulants: For Most, but Not for All!. <i>Cardiology</i> , 2019, 143, 121-123.	0.6	2
32	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). <i>BMC Cardiovascular Disorders</i> , 2019, 19, 165.	0.7	29
33	Devices in Heart Failure Patients – Who Benefits From ICD and CRT?. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 111.	1.1	17
34	Strategies in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants (NOACs) and co-medications with possible drug-drug interaction. <i>European Heart Journal</i> , 2019, 40, 3802-3802.	1.0	2
35	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	1.2	45
36	Acute Hemoptysis and Bronchoscopic Follow-up After Cryoablation of the Pulmonary Veins. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2019, 26, e37-e40.	0.8	2

#	ARTICLE	IF	CITATIONS
37	The year in cardiology 2018: arrhythmias and cardiac devices. <i>European Heart Journal</i> , 2019, 40, 803-808.	1.0	1
38	Design and rationale of the Edoxaban Treatment in routine clinical practice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 97-104.	0.6	24
39	Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population. <i>Clinical Therapeutics</i> , 2019, 41, 107-117.	1.1	43
40	Idarucizumab in the "real world": possibilities and limitations. <i>Europace</i> , 2019, 21, 359-360.	0.7	1
41	"Ten Commandments" of the EHRA Guide for the Use of NOACs in AF. <i>European Heart Journal</i> , 2018, 39, 1322-1322.	1.0	8
42	Stroke prevention in atrial fibrillation: re-defining "real-world data" within the broader data universe. <i>European Heart Journal</i> , 2018, 39, 2932-2941.	1.0	22
43	Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2018, 260, 82-87.	0.8	20
44	The year in cardiology 2017: arrhythmias and cardiac devices. <i>European Heart Journal</i> , 2018, 39, 434-441.	1.0	3
45	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	0.7	194
46	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
47	Providing practical answers to practical questions for NOAC therapy. <i>Cardiology Journal</i> , 2018, 25, 441-442.	0.5	0
48	Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium. <i>European Heart Journal</i> , 2017, 38, ehw578.	1.0	9
49	Impact of gender on event rates at 1-year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	0.8	30
50	A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. <i>Heart Rhythm</i> , 2017, 14, 1375-1379.	0.3	251
51	The Year in Cardiology 2016: arrhythmias and cardiac implantable electronic devices. <i>European Heart Journal</i> , 2017, 38, ehw629.	1.0	1
52	Long-term incidence of inappropriate shocks in patients with implantable cardioverter defibrillators in clinical practice: an underestimated complication?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 219-226.	0.6	20
53	The Subcutaneous Implantable Cardioverter Defibrillator. <i>European Heart Journal</i> , 2017, 38, 226-228.	1.0	6
54	Insertion of miniaturized cardiac monitors outside the catheter operating room: experience and practical advice. <i>Europace</i> , 2017, 19, 1624-1629.	0.7	13

#	ARTICLE	IF	CITATIONS
55	First experience with edoxaban and atrial fibrillation ablation – Insights from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2017, 244, 192-195.	0.8	19
56	Atypical presentation of false asystole detection in implantable loop recorder. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221280.	0.2	0
57	The subcutaneous implantable cardioverter defibrillator in daily clinical practice. <i>Swiss Medical Weekly</i> , 2017, 147, w14518.	0.8	1
58	Effect of Gender on Outcomes After Cardiac Resynchronization Therapy in Patients With a Narrow QRS Complex. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	19
59	Clinical performance of a new bidirectional rotational mechanical lead extraction sheath. <i>Europace</i> , 2016, 18, 253-256.	0.7	15
60	Non-vitamin K oral anticoagulants in –valvular–™ atrial fibrillation: a call for action. <i>Europace</i> , 2016, 18, 1-3.	0.7	44
61	The year in cardiology 2015: arrhythmias and device therapy. <i>European Heart Journal</i> , 2016, 37, 587-593.	1.0	0
62	Does implantation technique influence lead failure?. <i>Acta Cardiologica</i> , 2015, 70, 581-586.	0.3	8
63	Magnetic field interaction between a left ventricular assist device controller and a cardiac resynchronization therapy-defibrillator. <i>Europace</i> , 2015, 17, 1719-1719.	0.7	0
64	Incidence and Prognosis of Ventricular Arrhythmias in Patients with Congenital Left Ventricular Aneurysms or Diverticula. <i>American Journal of Medicine</i> , 2015, 128, 653.e1-653.e6.	0.6	13
65	Compression coil provides increased lead control in extraction procedures. <i>Europace</i> , 2015, 17, 499-503.	0.7	8
66	Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patients. <i>International Journal of Cardiology</i> , 2015, 185, 250-255.	0.8	15
67	Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. <i>European Heart Journal</i> , 2015, 36, 2780-2789.	1.0	55
68	Outcome of super-responders to cardiac resynchronization therapy defined by endpoint-derived parameters of left ventricular remodeling: a two-center retrospective study. <i>Clinical Research in Cardiology</i> , 2015, 104, 136-144.	1.5	4
69	Completely Epicardial Implantation of a Cardiac Resynchronization Therapy Defibrillator Using a Minimal Invasive Approach. <i>Thoracic and Cardiovascular Surgeon</i> , 2014, 62, 070-072.	0.4	2
70	Mechanical dyssynchrony in CRT: still searching for the Holy Grail. <i>European Heart Journal</i> , 2014, 35, 13-15.	1.0	3
71	An Unusual Reason for Loss of Biventricular Pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 383-386.	0.5	0
72	Superresponse to Cardiac Resynchronization Therapy. <i>Circulation</i> , 2014, 130, 87-90.	1.6	50

#	ARTICLE	IF	CITATIONS
73	Long-Term Performance of Modern Coronary Sinus Leads in Cardiac Resynchronization Therapy. Indian Pacing and Electrophysiology Journal, 2014, 14, 112-120.	0.3	5
74	Comprehensive cardiac resynchronization therapy optimization in the real world. Cardiology Journal, 2014, 21, 316-324.	0.5	9
75	Results of transvenous lead extraction of coronary sinus leads in patients with cardiac 4,703 resynchronization therapy. Chinese Medical Journal, 2013, 126, 4703-6.	0.9	3
76	Rhythm disorders in isolated left ventricular noncompaction. Annals of Medicine, 2012, 44, 101-108.	1.5	28
77	Long-Term Follow-up of Patients With Isolated Left Ventricular Noncompaction - Role of Electrocardiography in Predicting Poor Outcome -. Circulation Journal, 2011, 75, 1728-1734.	0.7	21
78	Characteristics and long-term outcome of echocardiographic super-responders to cardiac resynchronisation therapy: 'real world' experience from a single tertiary care centre. Heart, 2011, 97, 1668-1674.	1.2	50
79	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European Heart Journal, 2011, 32, 1968-1976.	1.0	61
80	Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. European Heart Journal, 2010, 31, 236-242.	1.0	66
81	Current practice of cardiac resynchronization therapy (CRT) in the real world: insights from the European CRT survey. European Heart Journal, 2009, 30, 2433-2435.	1.0	5
82	Electrophysiological findings in patients with isolated left ventricular non-compaction. Europace, 2009, 11, 1193-1200.	0.7	41
83	Electrocardiographic Characteristics at Initial Diagnosis in Patients With Isolated Left Ventricular Noncompaction. American Journal of Cardiology, 2009, 104, 984-989.	0.7	95
84	Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. Journal of Cardiovascular Medicine, 2009, 10, 616-623.	0.6	23
85	Drug-eluting stentsâ€”what should be improved?. Annals of Medicine, 2008, 40, 242-252.	1.5	37
86	Drug-Eluting Stent and Coronary Thrombosis. Circulation, 2007, 115, 1051-1058.	1.6	850
87	Dimethyl Sulfoxide Inhibits Tissue Factor Expression, Thrombus Formation, and Vascular Smooth Muscle Cell Activation. Circulation, 2006, 114, 1512-1521.	1.6	97
88	Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 349, 597-603.	1.0	11
89	Cocaine unbalances endothelial tissue factor andÂtissue factor pathway inhibitor expression. Journal of Molecular and Cellular Cardiology, 2006, 40, 746-749.	0.9	25
90	Cyclooxygenase-2 Inhibition and Coagulation. Journal of Cardiovascular Pharmacology, 2006, 47, S15-S20.	0.8	31

#	ARTICLE	IF	CITATIONS
91	Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH 2 Kinase Activation. Circulation Research, 2006, 99, 149-155.	2.0	110
92	Tissue Factor in Cardiovascular Diseases. Circulation, 2006, 113, 722-731.	1.6	439
93	Celecoxib Decreases Endothelial Tissue Factor Expression Through Inhibition of c-Jun Terminal NH 2 Kinase Phosphorylation. Circulation, 2005, 111, 1685-1689.	1.6	111
94	Rapamycin, but Not FK-506, Increases Endothelial Tissue Factor Expression. Circulation, 2005, 112, 2002-2011.	1.6	158
95	Histamine Induces Tissue Factor Expression. Circulation, 2005, 112, 341-349.	1.6	133